A new partnership has been confirmed between MOIC and the pharmaceutical company Sunovion Pharmaceuticals Europe Ltd. The partnership will focus on medicines optimisation in mental health and the company will work with the centre to communicate and facilitate education/learning, innovative approaches to medicines management and exchange of best practice. The outputs of this partnership will be an enhancement of medicines optimisation in mental health resulting in efficiencies and improved patient care via pathway improvements, training and drug protocols.

Partners in medicines optimisation
Although the Centre is based in Antrim, the programme of activity will extend beyond Northern Ireland to other parts of the United Kingdom and further afield in the future. Professor Mike Scott, Director of MOIC, welcomed the partnership and stated that “working in collaboration with industry, on the Medicines Optimisation agenda, is a key objective of the regional centre”.
Terry Petersen, Country Manager UK of Sunovion Pharmaceuticals Europe, added “Ensuring that patients receive appropriate medicines is core to the values of Sunovion and we are delighted that MOIC has formed a partnership with us to deliver this most important initiative. As a company, with an unwavering commitment to support people with psychiatric conditions, we view this as a very important project for us.’’

Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Additional information about Sunovion Pharmaceuticals Europe is available through its corporate website www.sunovion.eu.
Sunovion Pharmaceuticals Inc. an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions.